Drugs Containing Excipient (Inactive Ingredient) PEG-20 SORBITAN STEARATE

« Back to Dashboard

Generic drugs containing PEG-20 SORBITAN STEARATE excipient

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	ibuprofen	50090-4228	PEG-20 SORBITAN STEARATE
A-S Medication Solutions	ibuprofen	50090-4230	PEG-20 SORBITAN STEARATE
Method Pharmaceuticals LLC	ibuprofen	58657-680	PEG-20 SORBITAN STEARATE
RedPharm Drug Inc	ibuprofen	67296-1573	PEG-20 SORBITAN STEARATE

PEG-20 Sorbitan Stearate Market Dynamics, Suppliers, Applications, and Financial Outlook

Last updated: September 23, 2026

PEG-20 sorbitan stearate, commonly identified as polysorbate 60, is a nonionic surfactant used primarily as an emulsifier, solubilizer, wetting agent, and stabilizer. Its commercial demand is driven more by cosmetics, food, and topical pharmaceutical products than by injectable biologics. The market is fragmented, and manufacturers generally report sales within broader surfactant, excipient, or personal-care portfolios rather than disclosing revenue for PEG-20 sorbitan stearate alone.

The product has a stable demand profile but limited high-growth exposure. Its strongest commercial attributes are broad regulatory acceptance, established manufacturing technology, and compatibility with oil-in-water emulsions. Its main constraints are lower use in parenteral biologics than polysorbate 20 or polysorbate 80, sensitivity to oxidative and hydrolytic degradation, and substitution by other emulsifiers and surfactants.

What is PEG-20 sorbitan stearate?

PEG-20 sorbitan stearate is the polyoxyethylene derivative of sorbitan monostearate. It is also known as:

Attribute	Description
Common name	Polysorbate 60
INCI name	Polysorbate 60
Chemical description	Polyoxyethylene (20) sorbitan monostearate
CAS number	9005-67-8
Functional class	Nonionic surfactant and emulsifier
Physical form	Typically waxy solid, paste, or flakes
Primary lipophilic component	Stearic acid ester
Hydrophilic component	Polyoxyethylene chain
Typical HLB classification	Approximately 14 to 15, depending on grade and test method
Main applications	Creams, lotions, emulsions, oral products, food systems, and selected pharmaceutical formulations

Polysorbate 60 is chemically related to polysorbate 20 and polysorbate 80. The fatty-acid chain differentiates the materials: lauric acid for polysorbate 20, oleic acid for polysorbate 80, and stearic acid for polysorbate 60.

What are the main applications of PEG-20 sorbitan stearate?

PEG-20 sorbitan stearate is used where manufacturers need stable emulsification between aqueous and oil phases.

Pharmaceutical and nutraceutical applications

Pharmaceutical uses include:

• Topical creams and ointments
• Emulsions and lotions
• Oral liquid and semisolid products
• Suspensions and dispersions
• Tablet and capsule formulations
• Selected vaccine, diagnostic, and biologic formulations
• Drug-delivery systems requiring nonionic surface activity

Polysorbate 60 is less prominent in injectable biologics than polysorbate 20 and polysorbate 80. Injectable formulations typically prioritize low peroxide levels, low particulate burden, tight control of fatty-acid composition, and demonstrated compatibility with the active ingredient. Formulators often select polysorbate 20 or 80 because of established precedent in monoclonal antibodies and other protein products.

The FDA Inactive Ingredient Database records excipient use by route and dosage form. The database is a key regulatory reference for determining whether a proposed level and route have precedent in approved products (U.S. Food and Drug Administration, n.d.-a).

Cosmetics and personal care

Cosmetics represent a major commercial outlet. Polysorbate 60 is used in:

• Moisturizers
• Cold creams
• Facial creams
• Sunscreen emulsions
• Hair conditioners
• Cleansing products
• Makeup and color cosmetics
• Fragrance and essential-oil dispersions

Cosmetic demand benefits from the material’s emulsification performance, relatively mild sensory profile, and compatibility with fatty alcohols, mineral oils, esters, and botanical oils.

Food applications

Polysorbate 60 is used as an emulsifier and stabilizer in certain food systems. In the United States, polysorbate 60 is regulated as a direct food additive under 21 C.F.R. provisions governing emulsifying, stabilizing, and thickening agents. The European Union identifies polysorbate 60 as food additive E435 under its applicable additive framework.

Food demand is mature. Volume growth is tied to processed foods, bakery products, whipped systems, and formulation changes rather than rapid expansion of a new therapeutic category.

How large is the PEG-20 sorbitan stearate market?

No major public manufacturer reports PEG-20 sorbitan stearate as a standalone revenue line. Market research companies generally group it under polysorbates, nonionic surfactants, emulsifiers, specialty chemicals, cosmetic ingredients, or pharmaceutical excipients.

That reporting structure makes product-specific market-size estimates unreliable. The commercial market should be assessed through end-use indicators:

Market driver	Impact on PEG-20 sorbitan stearate
Topical pharmaceutical production	Positive
Skin-care and personal-care growth	Positive
Processed-food production	Stable to moderately positive
Injectable biologics	Limited positive effect
Demand for polysorbate 20 and 80	Competitive pressure
Clean-label and naturally derived emulsifiers	Substitution pressure
Tight excipient qualification standards	Positive for qualified suppliers
Ethylene oxide and fatty-acid costs	Margin volatility
Regional manufacturing concentration	Supply-chain risk

The product’s revenue trajectory is likely to be low- to mid-single-digit growth in established markets, with higher growth in selected Asian personal-care and pharmaceutical markets. That is an analytical market direction, not a disclosed product-specific forecast.

Which companies manufacture PEG-20 sorbitan stearate?

Supply is divided between multinational chemical companies, specialty excipient manufacturers, regional cosmetic-ingredient suppliers, and pharmaceutical distributors.

Representative supplier groups include:

Supplier or channel	Relevant commercial position
Croda	Pharmaceutical and cosmetic polysorbate grades, including Tween-branded materials
BASF	Nonionic surfactants and pharmaceutical excipient products, including Kolliphor-branded materials
Merck/Sigma-Aldrich	Laboratory, formulation-development, and selected pharmaceutical-grade supply
NOF Corporation	Pharmaceutical excipients and surfactants, particularly in Asian markets
Spectrum Chemical and regional distributors	Small- and medium-volume pharmaceutical and laboratory supply
Chinese and Indian manufacturers	Cost-competitive industrial, cosmetic, and selected pharmaceutical grades

Product qualification depends on more than the active ingredient name. Buyers typically assess:

• Compendial compliance
• Residual ethylene oxide and related impurities
• Peroxide and aldehyde levels
• Water content
• Acid value and saponification value
• Hydroxyl value
• Fatty-acid distribution
• Microbial limits
• Elemental impurities
• Batch-to-batch consistency
• Packaging and storage controls
• Change-control procedures
• Supply continuity

Premium pharmaceutical grades command higher prices because of analytical testing, documentation, GMP controls, and customer qualification. Cosmetic and industrial grades compete more directly on price.

What drives PEG-20 sorbitan stearate pricing?

Pricing is linked to raw-material and conversion costs rather than to intellectual-property exclusivity.

The principal cost inputs are:

1. Ethylene oxide and polyethylene glycol chemistry.
2. Stearic acid or stearic-rich fatty-acid feedstock.
3. Sorbitan and esterification intermediates.
4. Energy, utilities, and waste treatment.
5. Pharmaceutical-grade testing and quality systems.
6. Packaging, freight, and inventory requirements.

Ethylene oxide pricing can affect the polyoxyethylene portion of the molecule, while palm-derived and tallow-derived fatty-acid markets influence stearic-acid costs. Buyers increasingly evaluate feedstock origin, palm sustainability, animal-derived content, and regional regulatory requirements.

Pharmaceutical customers generally accept higher prices for validated grades because changing an excipient can trigger formulation, stability, process, and regulatory work. That switching cost gives qualified suppliers greater pricing power than commodity-grade producers.

How does PEG-20 sorbitan stearate compare with polysorbate 20 and polysorbate 80?

Attribute	Polysorbate 20	Polysorbate 60	Polysorbate 80
Fatty-acid component	Lauric acid	Stearic acid	Oleic acid
Typical physical form	Liquid or semiliquid	Waxy solid or paste	Liquid or semiliquid
Common use	Biologics, vaccines, cosmetics	Creams, emulsions, food, topical products	Biologics, vaccines, emulsions
Injectable biologic precedent	High	Lower	High
Oxidation concerns	Present	Present	Often significant because of unsaturation
Main commercial strength	Protein formulation precedent	Emulsion and cream performance	Broad pharmaceutical and biologic use
Substitution risk to PEG-20 sorbitan stearate	High in some pharmaceutical uses	Not applicable	High in selected applications

Polysorbate 60 has a saturated stearate chain, which can provide different oxidative behavior from polysorbate 80. Its solid form can complicate processing but can also support semisolid and cream products. In protein formulations, the established regulatory history of polysorbate 20 and 80 gives those products a stronger position.

What regulatory status applies to PEG-20 sorbitan stearate?

PEG-20 sorbitan stearate is regulated by application and grade rather than through a single global approval.

United States

Relevant regulatory pathways include:

• FDA Inactive Ingredient Database precedent for pharmaceutical products
• United States Pharmacopeia and National Formulary standards where applicable
• Food-additive provisions under Title 21 of the Code of Federal Regulations
• Cosmetic ingredient requirements under the Federal Food, Drug, and Cosmetic Act

An excipient is not approved as an independent drug. Its regulatory acceptability depends on the finished-product route, concentration, specification, manufacturing controls, and safety justification.

European Union

The material may be assessed under:

• European Pharmacopoeia requirements where a relevant monograph applies
• EU food-additive rules
• REACH obligations for chemical substances
• Cosmetic Products Regulation requirements
• Finished-product marketing authorization requirements

Asia-Pacific

China, India, Japan, South Korea, and Southeast Asian markets apply national pharmacopeial, food, cosmetic, and chemical-control requirements. Local registration and import documentation can influence supplier selection, particularly for pharmaceutical-grade materials.

What patents protect PEG-20 sorbitan stearate?

PEG-20 sorbitan stearate is an established chemical substance with no meaningful product-level exclusivity comparable to a patented active pharmaceutical ingredient.

IP category	Current commercial relevance
Basic molecule composition	Generally outside modern exclusivity periods
Manufacturing process	May be protected by process or formulation patents
High-purity grades	Trade secrets, specifications, and know-how are important
Low-peroxide formulations	Possible formulation and process protection
Drug-delivery systems	Product-specific patents may cover use with the excipient
Cosmetic compositions	Brand- or formula-specific patent claims may apply
Supplier trademarks	Commercially important but not composition exclusivity

There is no Orange Book listing for PEG-20 sorbitan stearate as an excipient. It is not an active pharmaceutical ingredient with standalone New Drug Application exclusivity. Paragraph IV litigation and abbreviated new drug application challenges therefore do not apply to the excipient itself. FDA Orange Book listing rules concern approved drug products and their associated patents, not general excipient ownership (U.S. Food and Drug Administration, n.d.-b).

What patent litigation and licensing issues affect the market?

Direct patent litigation over PEG-20 sorbitan stearate is unlikely to determine market access. The more relevant legal risks arise at the finished-product level.

These risks include:

• Patent claims covering a drug formulation that uses polysorbate 60
• Manufacturing patents covering a particular emulsion or delivery system
• Patent claims directed to particle size, impurity control, or stabilization
• Trademark disputes involving supplier brands
• Trade-secret disputes over purification and low-peroxide manufacturing
• Contract restrictions imposed by qualified pharmaceutical suppliers

Licensing deals are generally tied to a drug product, delivery platform, or branded formulation. Public companies rarely disclose a separate license fee or royalty stream for the excipient itself.

When does PEG-20 sorbitan stearate lose exclusivity?

PEG-20 sorbitan stearate does not have a single patent expiration date or regulatory exclusivity date. The basic compound is a mature excipient. Commercial differentiation instead depends on:

• Grade qualification
• Customer-specific specifications
• Regulatory files and supporting documentation
• Manufacturing consistency
• Supplier audits
• Technical service
• Capacity and delivery reliability
• Sustainability documentation

A pharmaceutical customer may take months or years to qualify a replacement supplier even when the chemical identity is unchanged. This creates practical retention for established suppliers without creating legal exclusivity.

What generic entry risks exist for products using PEG-20 sorbitan stearate?

Generic entry risk depends on the finished drug, not on the excipient.

For topical and oral products, a generic manufacturer may substitute another approved emulsifier if the formulation, bioequivalence, stability, and regulatory requirements permit it. For complex emulsions, ophthalmic products, injectables, and biologics, excipient substitution is more difficult.

The main commercial risks are:

• Formulation redesign by generic manufacturers
• Use of polysorbate 20 or 80 in place of polysorbate 60
• Adoption of poloxamers, sucrose esters, lecithin, or other emulsifiers
• Direct sourcing from lower-cost Asian suppliers
• Customer dual-sourcing programs
• Reduced use in products where the excipient has limited injectable precedent

What is the financial trajectory for PEG-20 sorbitan stearate?

The most likely trajectory is stable growth with margin separation between commodity and pharmaceutical grades.

Segment	Volume outlook	Margin outlook
Industrial and food grade	Low to moderate growth	Competitive
Cosmetic grade	Moderate growth	Moderate
Topical pharmaceutical grade	Moderate growth	Stronger
Injectable or biologic-grade applications	Selective growth	Highest qualification premium
Laboratory and small-pack supply	Stable	High unit margin, limited volume

Revenue expansion will depend on personal-care consumption, pharmaceutical topical products, and increased use of specialty excipients in complex formulations. Profitability will depend on raw-material pass-through, plant utilization, quality costs, and the ability to maintain premium pharmaceutical grades.

The principal upside is greater demand for validated excipients in regulated markets. The principal downside is substitution by better-established polysorbates in biologics and by newer or naturally positioned emulsifiers in cosmetics and food.

How strong is the supplier and manufacturing position?

Supplier strength is moderate rather than protected by patents. The strongest manufacturers have:

• Multiple production sites or qualified backup capacity
• Compendial and regulatory documentation
• Low-impurity and low-peroxide grades
• Strong change-control systems
• Global distribution
• Validated pharmaceutical customers
• Capability to support audits and regulatory filings

Manufacturing barriers are operational and regulatory. Esterification, ethoxylation, purification, drying, and packaging must be controlled to produce consistent material. The molecule itself is not difficult to copy, but producing a reliable pharmaceutical grade at scale requires process control and customer qualification.

Geographic diversification is increasingly important. Buyers may prefer suppliers with production in Europe, North America, China, India, or Japan to reduce freight, geopolitical, and single-site risks.

Key Takeaways

• PEG-20 sorbitan stearate is commonly marketed as polysorbate 60.
• Its largest commercial opportunities are cosmetics, food, topical pharmaceuticals, and oral formulations.
• Polysorbate 20 and polysorbate 80 have stronger positions in injectable biologics.
• No standalone Orange Book exclusivity, Paragraph IV pathway, or product-level patent monopoly applies to the excipient.
• Supplier differentiation depends on grade quality, impurity control, documentation, and reliability.
• Market growth is likely to be moderate, with pharmaceutical-grade products generating stronger margins than commodity grades.
• Public financial reporting does not isolate PEG-20 sorbitan stearate revenue; the appropriate analysis uses polysorbate, nonionic surfactant, specialty excipient, cosmetic ingredient, and food-additive segments as proxies.
• The largest threats are substitution, commodity pricing, raw-material volatility, and lower-cost regional competition.

FAQs

Is PEG-20 sorbitan stearate the same as polysorbate 60?

Yes. PEG-20 sorbitan stearate is commonly identified as polyoxyethylene (20) sorbitan monostearate, or polysorbate 60. Commercial grades can differ in fatty-acid distribution, residual impurities, water content, and performance.

Is PEG-20 sorbitan stearate suitable for injectable drugs?

It can be used only when the specific grade, concentration, route, stability profile, and finished-product regulatory requirements are supported. Polysorbate 20 and polysorbate 80 have broader precedent in injectable biologics.

Does PEG-20 sorbitan stearate have an Orange Book patent?

No. The excipient itself does not have an Orange Book patent listing. Any relevant patent risk would normally arise from the finished drug formulation or delivery system.

What are the main alternatives to PEG-20 sorbitan stearate?

Alternatives include polysorbate 20, polysorbate 80, poloxamers, sucrose esters, lecithin, sorbitan esters, fatty alcohol ethoxylates, and other nonionic emulsifiers. Suitability depends on dosage form, stability, route, and regulatory history.

Which quality attributes most affect pharmaceutical purchasing decisions?

The main attributes are peroxide value, aldehyde levels, fatty-acid composition, water content, microbial quality, elemental impurities, residual ethylene oxide, batch consistency, packaging, and change-control performance.

References

European Commission. (n.d.). Food additives database: E435 polysorbates. https://food.ec.europa.eu

U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

U.S. Food and Drug Administration. (n.d.-c). Title 21, Code of Federal Regulations, food additives. https://www.ecfr.gov

United States Pharmacopeial Convention. (n.d.). United States Pharmacopeia and National Formulary. https://www.usp.org.